-
International Journal of Cardiology Nov 2010This is the fourth in a series of letters-to-the-editor discussing phentermine and cardiovascular safety. Yosefy et al., in reporting a case of aortic cusp tear in a 28...
This is the fourth in a series of letters-to-the-editor discussing phentermine and cardiovascular safety. Yosefy et al., in reporting a case of aortic cusp tear in a 28 year-old woman with a bicuspid aortic valve, attributed the tear to previous phentermine therapy. Evidence of mitral and tricuspid valve thickening was noted at echocardiography. In replying we pointed out that phentermine-induced valvular heart disease has not been reported and suggested that, since the reference cited for support referred to fenfluramine-induced valvulopathy, the attribution of the cusp tear to phentermine was incorrect. Yosefy replied, asserting that since the patient had no other cardiac risk factor, the tear had to be due to phentermine. In support of his presumption that phentermine therapy can induce cardiac risk he cited only the PDR warnings for phentermine. In this reply we point out that a congenital bicuspid valve should not be ignored as a cardiac risk factor, that aortic valve cusp tears have been associated with bicuspid valves but never with phentermine or with valve thickening no matter the etiology, and that there is no published data implicating phentermine as a cause of valve thickening (or any other valve pathology). Evidence of phentermine safety in the peer-reviewed medical literature is discussed in the context of the cardiovascular warnings for phentermine in the PDR.
Topics: Female; Heart Valve Diseases; Humans; Mitral Valve; Phentermine; Risk Factors
PubMed: 20207432
DOI: 10.1016/j.ijcard.2010.02.060 -
Journal of Clinical Psychopharmacology Dec 1996
Topics: Adult; Appetite Depressants; Family; Humans; Male; Obesity; Phentermine; Psychoses, Substance-Induced
PubMed: 8959483
DOI: 10.1097/00004714-199612000-00020 -
Lancet (London, England) Jul 2011
Topics: Anti-Obesity Agents; Drug Combinations; Fructose; Heart Valve Diseases; Humans; Obesity; Phentermine; Topiramate; Weight Loss
PubMed: 21742167
DOI: 10.1016/S0140-6736(11)61080-5 -
The Korean Journal of Gastroenterology... Mar 2024The prevalence of obesity with various complications is increasing rapidly in Korea. Although lifestyle modification is fundamental in obesity treatment, more effective... (Review)
Review
The prevalence of obesity with various complications is increasing rapidly in Korea. Although lifestyle modification is fundamental in obesity treatment, more effective treatment tools are required. Many advances in obesity treatment have been reported recently, including lifestyle modifications and pharmacological, endoscopic, and surgical treatments. Drugs with proven long-term efficacy and safety are preferred because management for obesity treatment is a long-term process. Currently, four medications are available for long-term use in Korea: Orlistat, Naltrexone/bupuropion NR, Phentermine/topiramate capsule, and Liraglutide. Recently, semaglutide and tirzepatide have been attracting attention because of their effectiveness and convenience, but they are not yet available in Korea. In addition, there are limitations such as the yo-yo effect when discontinuing the drug, long-term safety, and cost. Patients and medical staff must be aware of the advantages and side effects of each medication to ensure the successful treatment of obesity.
Topics: Humans; Anti-Obesity Agents; Phentermine; Obesity; Orlistat; Liraglutide
PubMed: 38522852
DOI: 10.4166/kjg.2024.016 -
Life Sciences 1996Drug discrimination studies were conducted in six male Sprague-Dawley rats trained to discriminate the interoceptive cues produced by 10 mg/kg cocaine in an effort to...
Drug discrimination studies were conducted in six male Sprague-Dawley rats trained to discriminate the interoceptive cues produced by 10 mg/kg cocaine in an effort to investigate if there is stimulus generalization to phentermine or phentermine + fenfluramine. Once having reached criterion performance, these rats were tested with lower doses of cocaine and generated a typical dose-response curve allowing for calculation of an ED50 value: 2.798 mg/kg. Testing of phentermine in doses of 1.25-5.0 mg/kg indicated generalization with the highest dose producing 80% cocaine-appropriate responding and allowing for an ED50 value of 2.356 mg/kg. When the phentermine doses were tested in combination 2.0 mg/kg fenfluramine, however, there was an increase in the discriminability of the highest phentermine dose and a slight decrease in the ED50 value of the combination. Thus, administration of phentermine + fenfluramine, having both dopamine-releasing and serotonin-releasing properties, respectively, may mimic the neurochemical activity by which cocaine acts in the central nervous system and may possibly allow for cocaine-like effects as these two drugs see increased use in obesity control.
Topics: Animals; Cocaine; Discrimination, Psychological; Dose-Response Relationship, Drug; Fenfluramine; Male; Phentermine; Rats; Rats, Sprague-Dawley
PubMed: 8890951
DOI: 10.1016/s0024-3205(96)00513-9 -
Diabetes, Obesity & Metabolism Oct 2011
Topics: Appetite Depressants; Delayed-Action Preparations; Diabetic Angiopathies; Dyslipidemias; Female; Humans; Male; Obesity; Phentermine; Weight Loss
PubMed: 21896124
DOI: 10.1111/j.1463-1326.2011.01435.x -
International Journal of Obesity 1983Fifty women with refractory obesity received phentermine resinate. Seven were withdrawn because of side-effects: three developed severe headaches, one each hypertension,...
Fifty women with refractory obesity received phentermine resinate. Seven were withdrawn because of side-effects: three developed severe headaches, one each hypertension, depressive symptoms, breathlessness and palpitations with irritability. The mean weight loss in the 34 who completed the 20-week study was 6.4 kg. Nine lost 10 kg or more. Sustained appetite suppression was related to weight loss. Plasma phentermine concentrations did not correlate with the severity of the obesity problem, the degree of subjective anorexia or with weight loss. Poor initial response to standard dosage of phentermine is unlikely to improve with higher dosage. The individual's response to phentermine is unpredictable and appears to relate to factors other than the plasma drug concentration.
Topics: Adolescent; Adult; Aged; Appetite Depressants; Body Weight; Female; Humans; Ion Exchange Resins; Middle Aged; Obesity; Phentermine
PubMed: 6654575
DOI: No ID Found -
Childhood Obesity (Print) Dec 2023Pharmacotherapy has emerged as a practical option for weight management in pediatrics. This study aims to assess the effectiveness and safety of phentermine use in...
Pharmacotherapy has emerged as a practical option for weight management in pediatrics. This study aims to assess the effectiveness and safety of phentermine use in pediatric patients with obesity. We performed a retrospective single-center analysis of patients younger than or equal to 18 years of age, over 10 years, who underwent phentermine treatment and recommended lifestyle changes. We evaluated efficacy by the change in the percent of the 95th percentile for BMI (%BMIp95). We deemed a 5% decrease in %BMIp95 as a favorable outcome. We identified 30 pediatric patients who were treated with phentermine. The cohort was primarily female, 63% white, with a mean (standard deviation) baseline age of 15.63 (1.97) years. The average duration of treatment was 10 months, with a period ranging from 2 weeks to 2 years. The average %BMIp95 at the start of treatment was 137%, and that at the time of analysis was 122%, with a mean reduction of 15%. Five patients, 17%, experienced side effects that resolved after dose reduction or discontinuing phentermine. Phentermine monotherapy is an effective and safe means for weight loss in pediatric patients when combined with lifestyle interventions. Twenty-one of 30 (70%) patients achieved at least a 5% decrease in %BMIp95 within a mean duration of treatment of 10 months. We noted no severe adverse events.
Topics: Humans; Female; Adolescent; Child; Phentermine; Retrospective Studies; Anti-Obesity Agents; Pediatric Obesity; Weight Loss
PubMed: 36576420
DOI: 10.1089/chi.2022.0147 -
American Journal of Therapeutics May 2023
Topics: Humans; Phentermine; Fenfluramine; Hypertension, Pulmonary; Obesity; Weight Loss
PubMed: 34117142
DOI: 10.1097/MJT.0000000000001387 -
Australian Family Physician 2017Obesity is a serious, chronic, relapsing disease of energy regulation, with strong genetic and early-life environmental determinants. Pharmacotherapy can be a useful...
BACKGROUND
Obesity is a serious, chronic, relapsing disease of energy regulation, with strong genetic and early-life environmental determinants. Pharmacotherapy can be a useful adjunct to lifestyle intervention in effecting and maintaining clinically meaningful weight loss.
OBJECTIVE
The aim of this article is to discuss the role of pharmacotherapy in obesity management. The efficacy, side effects and contraindications of available weight-loss medications are reviewed.
DISCUSSION
Long-term pharmacotherapy options, which can be effective in providing moderate weight loss, are available to treat obesity. Pharma-cotherapy should be considered an adjunct to lifestyle intervention in those with a body mass index (BMI) >30 kg/m30 kg/m2, or in those with a BMI of 27-30 kg/m2 and obesity-related complications. Safety and efficacy should be monitored closely on commencement, and the medication should be discontinued if there are safety or tolerability issues, or if.
Topics: Anti-Obesity Agents; Appetite Depressants; Body Mass Index; Drug Therapy; Drug Therapy, Combination; Fructose; Humans; Incretins; Lactones; Liraglutide; Obesity; Orlistat; Phentermine; Topiramate
PubMed: 28697290
DOI: No ID Found